<?xml version='1.0' encoding='utf-8'?>
<document id="26590007"><sentence text="Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs."><entity charOffset="24-33" id="DDI-PubMed.26590007.s1.e0" text="quinolone" /></sentence><sentence text="The study investigated whether quinolone antibiotics inhibit the PEPT1-mediated uptake of its substrates"><entity charOffset="31-40" id="DDI-PubMed.26590007.s2.e0" text="quinolone" /></sentence><sentence text=" Among the quinolones examined, lomefloxacin, moxifloxacin (MFLX) and purlifloxacin significantly inhibited the uptake of PEPT1 substrate phenylalanine-Ψ(CN-S)-alanine (Phe-Ψ-Ala) in HeLa/PEPT1 cells to 31"><entity charOffset="11-21" id="DDI-PubMed.26590007.s3.e0" text="quinolones" /><entity charOffset="32-44" id="DDI-PubMed.26590007.s3.e1" text="lomefloxacin" /><entity charOffset="46-58" id="DDI-PubMed.26590007.s3.e2" text="moxifloxacin" /><entity charOffset="60-64" id="DDI-PubMed.26590007.s3.e3" text="MFLX" /><entity charOffset="70-83" id="DDI-PubMed.26590007.s3.e4" text="purlifloxacin" /><entity charOffset="138-167" id="DDI-PubMed.26590007.s3.e5" text="phenylalanine-Ψ(CN-S)-alanine" /><entity charOffset="169-178" id="DDI-PubMed.26590007.s3.e6" text="Phe-Ψ-Ala" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e0" e2="DDI-PubMed.26590007.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e1" e2="DDI-PubMed.26590007.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e1" e2="DDI-PubMed.26590007.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e1" e2="DDI-PubMed.26590007.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e1" e2="DDI-PubMed.26590007.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e1" e2="DDI-PubMed.26590007.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e1" e2="DDI-PubMed.26590007.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e2" e2="DDI-PubMed.26590007.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e2" e2="DDI-PubMed.26590007.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e2" e2="DDI-PubMed.26590007.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e2" e2="DDI-PubMed.26590007.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e2" e2="DDI-PubMed.26590007.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e3" e2="DDI-PubMed.26590007.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e3" e2="DDI-PubMed.26590007.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e3" e2="DDI-PubMed.26590007.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e3" e2="DDI-PubMed.26590007.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e4" e2="DDI-PubMed.26590007.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e4" e2="DDI-PubMed.26590007.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e4" e2="DDI-PubMed.26590007.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e5" e2="DDI-PubMed.26590007.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26590007.s3.e5" e2="DDI-PubMed.26590007.s3.e6" /></sentence><sentence text="6 ± 1" /><sentence text="3%, 27" /><sentence text="6 ± 2" /><sentence text="9%, 36" /><sentence text="8 ± 2" /><sentence text="2% and 32" /><sentence text="6 ± 1" /><sentence text="4%, respectively" /><sentence text=" Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50 value of 4"><entity charOffset="33-41" id="DDI-PubMed.26590007.s12.e0" text="MFLX" /></sentence><sentence text="29 ± 1" /><sentence text="29 mm" /><sentence text=" In addition, MFLX significantly decreased the cephalexin and valacyclovir uptake in HeLa/PEPT1 cells"><entity charOffset="47-57" id="DDI-PubMed.26590007.s15.e0" text="cephalexin" /><entity charOffset="62-74" id="DDI-PubMed.26590007.s15.e1" text="valacyclovir" /><entity charOffset="14-25" id="DDI-PubMed.26590007.s15.e2" text="MFLX" /><pair ddi="false" e1="DDI-PubMed.26590007.s15.e2" e2="DDI-PubMed.26590007.s15.e2" /><pair ddi="false" e1="DDI-PubMed.26590007.s15.e2" e2="DDI-PubMed.26590007.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26590007.s15.e2" e2="DDI-PubMed.26590007.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26590007.s15.e0" e2="DDI-PubMed.26590007.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26590007.s15.e0" e2="DDI-PubMed.26590007.s15.e1" /></sentence><sentence text=" In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml)"><entity charOffset="152-155" id="DDI-PubMed.26590007.s16.e0" text="MFLX" /></sentence><sentence text=" The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h)"><entity charOffset="103-106" id="DDI-PubMed.26590007.s17.e0" text="MFLX" /></sentence><sentence text=" The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41"><entity charOffset="70-73" id="DDI-PubMed.26590007.s18.e0" text="MFLX" /></sentence><sentence text="7 ± 6" /><sentence text="2% and 49" /><sentence text="2 ± 9" /><sentence text="2%, respectively" /><sentence text=" The results indicate that administration of quinolone antibiotics concomitantly with PEPT1 substrate drugs may potentially result in drug-drug interaction"><entity charOffset="45-54" id="DDI-PubMed.26590007.s23.e0" text="quinolone" /></sentence><sentence text="" /></document>